This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stephen J. Peroutka, MD, PhD
Department of Neurology, C-338 Stanford University Medical Center Stanford, CA 94305

Arch Gen Psychiatry. 1989;46(2):191.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a ring-substituted amphetamine derivative that is chemically related to both hallucinogens and stimulants. The drug appears to have unique psychoactive properties and has been advocated by certain therapists as an adjunct to psychotherapy.¹ However, due to findings in laboratory animals² of neurotoxicity caused by MDMA and related compounds, the drug was placed on Schedule I by the Food and Drug Administration in July 1985. Significant controversy exists concerning the legal status of MDMA, its potential clinical efficacy, and, most importantly, the possibility that it may cause irreversible neurotoxicity in human users.³

In addition, undocumented reports have suggested that the recreational use of MDMA has been increasing at university campuses in the United States during the past few years. Although no formal epidemiological studies have been performed, a recent informal survey found that a significant number of students on an . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?